Skip to main content
. Author manuscript; available in PMC: 2022 Nov 4.
Published in final edited form as: Mol Cancer Ther. 2022 May 4;21(5):844–854. doi: 10.1158/1535-7163.MCT-21-0317

Figure 2. Structural modeling of FLT3 inhibitors bound to resistant mutants.

Figure 2.

(A) Mapped interactions focused upon Y693 residue with FF-10101, crenolanib, midostaurin, and quizartinib. Two-way arrows indicate distance (Å) between an aromatic moiety of each respective drug forming a π-π interaction with tyrosine. (B) Hinge region of FLT3 mapped interaction with FF-10101 and midostaurin. (C) FF-10101 and midostaurin mapped against D698. FF-10101 exhibits no interaction while the N-methyl moiety of midostaurin forms hydrogen bond with D698.